CreatorsPublishersAdvertisers
View more in
Cancer

Amivantamab Paves a New Treatment Path for Patients With EGFR Exon 20–Mutant NSCLC

onclive.com
 2021-07-14

Amivantamab ushers in a new era of targeted treatment for patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations. Amivantamab ushers in a new era of targeted treatment for patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations. This population accounts for approximately 4% to 10% of patients with NSCLC whose disease harbors an EGFR mutation and who are often resistant to treatment with available EGFR tyrosine kinase inhibitors (TKIs).1.

www.onclive.com

Comments / 0

Comments / 0